Inflammatory monocytes constrain YAP-driven cell proliferation, while TAZ promotes unchecked growth and mortality
Background
The Hippo pathway, with its transcriptional coactivators YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), is a crucial regulator of cell growth, organ development, and tissue homeostasis. While both are central to these processes, their structural distinctiveness suggests important independent functional differences that are not fully understood. Current cancer therapies often broadly target cell proliferation pathways, but a nuanced understanding of how specific isoforms like YAP and TAZ differentially influence cellular behavior and the immune microenvironment could unlock more precise and effective therapeutic strategies for diseases like colorectal cancer (CRC) and hepatocellular carcinoma (HCC).
Study Design
Researchers generated YAP- and TAZ-predominant clones within the liver to investigate their long-term behavior and distinct functional roles. The study observed the cellular dedifferentiation, immune cell recruitment, and growth dynamics of these clones. To explore the mechanism of YAP clonal clearance, inflammatory blood-derived monocytes were specifically inhibited. The findings from the preclinical model were then correlated with clinical outcomes by analyzing 5-year survival rates in patients with YAPHigh or TAZHigh colorectal cancer (CRC) and similar trends in hepatocellular carcinoma (HCC) patients.
Results
YAP-predominant clones rapidly induced cells into a stem cell-like dedifferentiated state, followed by robust inflammatory immune cell recruitment and subsequent clonal clearance. In stark contrast, TAZ-predominant clones fostered an anti-inflammatory immune environment, leading to their long-term maintenance, massive organ growth, and significantly increased mortality. The study specifically identified that YAP clones recruit inflammatory blood-derived monocytes, and crucially, if these monocytes were inhibited, YAP clonal growth was permitted, highlighting their suppressive role. Consistent with these preclinical observations, clinical data revealed a profound difference in patient outcomes: > Patients with YAPHigh colorectal cancer (CRC) exhibited a 67% 5-year survival rate, whereas patients with TAZHigh CRC did not survive to 5 years, demonstrating a 0% 5-year survival rate. Similar, though unspecified, trends were also observed in patients with hepatocellular carcinoma, underscoring the differential impact of these coactivators.
Key Findings
- YAP-predominant liver clones rapidly dedifferentiate cells and recruit inflammatory immune cells, leading to their clearance.
- TAZ-predominant liver clones promote an anti-inflammatory immune environment, resulting in massive organ growth and increased mortality.
- Inflammatory blood-derived monocytes are crucial for constraining YAP clonal growth; their inhibition permits YAP proliferation.
- Patients with YAPHigh colorectal cancer (CRC) had a 67% 5-year survival rate.
- Patients with TAZHigh colorectal cancer (CRC) did not survive to 5 years (0% 5-year survival).
Why It Matters
This research fundamentally shifts our understanding of YAP and TAZ as distinct drivers of disease progression, particularly in cancer. The findings suggest that targeting the immune microenvironment, specifically inflammatory monocytes, could be a viable strategy to modulate YAP-driven proliferation, while TAZ-driven cancers may require different approaches due to their pro-growth, anti-inflammatory environment. For clinicians and researchers, this implies that simply inhibiting the entire Hippo pathway might not be optimal; instead, therapies should consider the specific YAP/TAZ predominance. This work opens avenues for developing isoform-specific diagnostics and targeted therapies, moving beyond broad pathway inhibition towards precision oncology, though clinical translation is still in early stages, requiring extensive further research.
yap
taz
hippo-pathway
cell-proliferation
immune-modulation
monocytes